|
| Thursday, 10 September 2015, 16:56 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
|
| Drugs for Neglected Diseases initiative Eisai Co., Ltd. |
TOKYO, Sept 10, 2015 - (JCN Newswire) - The Drugs for Neglected Diseases initiative (DNDi) and the Japanese pharmaceutical company Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai's anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world's most neglected diseases.
Most probably transmitted through pricks to the skin by walking barefoot, eumycetoma is a chronic condition that affects people in tropical and subtropical regions, in particular across Africa, with the highest burden found in Sudan. The fungus penetrates the skin and causes massive tumour-like lesions that lead to serious disability, grave socioeconomic consequences, and stigma.
There is only one current treatment option, which is expensive, toxic, and only cures about 30% of patients even after twelve months of treatment. Those who aren't cured are at risk of repeated amputations as the infection spreads throughout the body.
Fosravuconazole, an azole-class antifungal drug discovered by Eisai, has shown in vitro and in vivo to have strong antifungal activities against eumycetoma. Under the terms of the agreement, DNDi and partners will be conducting the clinical development to assess safety and efficacy of fosravuconazole in patients with the disease, while Eisai provides DNDi with its scientific expertise as well as a supply of the drug for the clinical studies. Eisai also has the option to become DNDi's industrial partner to manufacture, register, and make available fosravuconazole at an affordable price to the public sector in endemic areas.
"We are very excited about the possibility of a new treatment against this terrible and neglected condition", said Dr Nathalie Strub-Wourgaft, Medical Director of DNDi. "Eumycetoma patients have received little attention and virtually no research and development has addressed their needs."
There are major knowledge gaps about mycetoma in general, including about its transmission, prevalence, route of infection, and susceptibility. The disease was only recently added to the World Health Organization (WHO) list of neglected tropical diseases in 2013, under 'other neglected conditions'.
"Mycetoma is a serious global health issue affecting mostly young adults in developing countries, particularly those of low socioeconomic status and manual workers such as agriculturalists, labourers and herdsmen", said Takashi Owa, Ph.D., Chief Innovation Officer, Eisai Co., Ltd. "As a human health care company, we are committed to developing a new treatment for this horrendous disease, thereby contributing to the lives of people in endemic areas."
Fosravuconazole will be investigated in a randomized controlled trial to study the efficacy of the drug compared to an existing therapy in moderate eumycetoma cases. This study is scheduled to start in 2016, and will be conducted by DNDi in collaboration with the Mycetoma Research Center (MRC) of the University of Khartoum, Sudan.
About the Drugs for Neglected Diseases initiative (DNDi)
A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected diseases, in particular leishmaniasis, human African trypanosomiasis, Chagas disease, specific filarial infections, paediatric HIV, mycetoma, and hepatitis C. Since its inception in 2003, DNDi has delivered six treatments: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole for Chagas disease. DNDi has established regional disease-specific platforms, which bring together partners in disease-endemic countries to strengthen existing clinical research capacity, as well as to build new capacity where necessary. www.dndi.org
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Mar 17, 2026 18:49 HKT/SGT |
|
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation |
| Mar 12, 2026 16:21 HKT/SGT |
|
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration |
| Mar 11, 2026 11:07 HKT/SGT |
|
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting |
| Mar 2, 2026 08:49 HKT/SGT |
|
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) |
| Feb 16, 2026 13:03 HKT/SGT |
|
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy |
| Feb 10, 2026 12:34 HKT/SGT |
|
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China |
| Feb 6, 2026 10:31 HKT/SGT |
|
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan |
| Jan 26, 2026 10:37 HKT/SGT |
|
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review |
| Jan 21, 2026 15:44 HKT/SGT |
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time |
| Jan 13, 2026 08:50 HKT/SGT |
|
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan |
| More news >> |
 |
|
|
|
